TCT 2023 | ISAR-DESIRE 3: 10-Year Results

In-stent restenosis (ISR) remains the primary limitation of percutaneous treatment for coronary artery disease. The strategy to address this limitation involves the use of drug-eluting stents (DES) or drug-coated balloons (DCB), both of which have proven to be effective and safe therapeutic alternatives.

TCT 2023 | SWEDEHEART, evolución  a 5 años

Despite current recommendations, treating ISR continues to be a challenge, and clinical trial evidence is limited. 

The objective of the Prospective Randomized ISAR-DESIRE 3 Study was to investigate the long-term incidence of recurrent revascularization after the treatment of ISR with drug-eluting stents.

The primary endpoint (PEP) was the need for repeat target lesion revascularization (R-TLR), defined as any repeated revascularization procedure over the 10-year follow-up.

A total of 402 patients were randomized to receive treatment with plain balloon (PB), DCB, or DES. At 10 years, R-TLR was required for 204 lesions, of which 82 were in the PB group, 70 in the DCB group, and 52 in the DES group. During the first year of follow-up, the risk of R-TLR was reduced with the use of DCB (hazard ratio [HR] = 0.36 [95% confidence interval (CI): 0.24-0.54]) and DES (HR = 0.23 [0.14-0.38]) compared with PB.

Read also: TCT 2023 | VIVA Trial: TAVR vs. SAVR in Patients with Severe Aortic Stenosis and Small Aortic Annulus.

After the first year, the risk of R-TLR was reduced non-significantly with DCB (HR = 0.77 [0.51-1.16]) and significantly with DES (HR = 0.61 [0.39-0.95]). The risk of DCB versus DES was similar during (HR = 1.54 [0.89-2.69]) and after 1 year (HR = 1.26 [0.82 – 1.92]).

Conclusion

In summary, the total number of R-TLR events after 10 years of DES-ISR treatment is high. The use of DCB and, in particular, of DES, are both alternatives to reduce the need for initial revascularization and recurrent revascularization compared with PB.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Recurrent Revascularization at 10 Years after Percutaneous Treatment of Drug Eluting Stent Restenosis.

Reference: Tobias Koch, MD et al TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...